DRAGONPHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
DRAGONPHARMA
Largest movements
- Cash -€67,020
down €67,020 (-97.5%), from €68,719 to €1,699
mainly Investment in fixed assets (net) (-€98,730) and Trade debts (-€40,808)
- Tangible fixed assets +€62,443
up €62,443 (+8.7%), from €714,543 to €776,986
of which Land and buildings: +€586,509
- Receivables within one year -€27,000
down €27,000 (-75.7%), from €35,681 to €8,681
of which Trade receivables: -€27,000
- Trade debts -€40,808
down €40,808 (-83.9%), from €48,662 to €7,854
- Accrued charges and deferred income +€13,090
up €13,090 (+52046.6%), from €25 to €13,115
- Gross operating margin +€5,961
up €5,961 (+25.6%), from €23,288 to €29,249
- Depreciation +€4,371
up €4,371 (+13.7%), from €31,916 to €36,287
- Other operating charges -€2,105
down €2,105 (-40.3%), from €5,217 to €3,112
- Financial charges -€568
down €568 (-27.1%), from €2,095 to €1,526
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €819,294 | €787,861 | -€31,433 | -3.8% |
| Fixed assets | 21/28 | €714,768 | €777,211 | +€62,443 | +8.7% |
| Tangible fixed assets | 22/27 | €714,543 | €776,986 | +€62,443 | +8.7% |
| Land and buildings | 22 | €190,477 | €776,986 | +€586,509 | +307.9% |
| Plant, machinery and equipment | 23 | €524,066 | €0 | -€524,066 | -100.0% |
| Financial fixed assets | 28 | €225 | €225 | = | 0.0% |
| Current assets | 29/58 | €104,525 | €10,650 | -€93,876 | -89.8% |
| Amounts receivable within one year | 40/41 | €35,681 | €8,681 | -€27,000 | -75.7% |
| Trade receivables | 40 | €27,168 | €168 | -€27,000 | -99.4% |
| Other amounts receivable | 41 | €8,513 | €8,513 | = | 0.0% |
| Cash at bank and in hand | 54/58 | €68,719 | €1,699 | -€67,020 | -97.5% |
| Deferred charges and accrued income | 490/1 | €125 | €270 | +€145 | +115.7% |
| Total equity and liabilities | 10/49 | €819,294 | €787,861 | -€31,433 | -3.8% |
| Equity | 10/15 | €364,465 | €355,790 | -€8,675 | -2.4% |
| Contributions | 10/11 | €18,550 | €18,550 | = | 0.0% |
| Reserves | 13 | €358,043 | €351,316 | -€6,727 | -1.9% |
| Tax-exempt reserves | 132 | €145,004 | €138,277 | -€6,727 | -4.6% |
| Distributable reserves | 133 | €213,039 | €213,039 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€12,128 | -€14,076 | -€1,948 | -16.1% |
| Provisions and deferred taxes | 16 | €60,909 | €57,911 | -€2,999 | -4.9% |
| Deferred taxes | 168 | €60,909 | €57,911 | -€2,999 | -4.9% |
| Amounts payable | 17/49 | €393,919 | €374,160 | -€19,759 | -5.0% |
| Amounts payable after more than one year | 17 | €328,191 | €335,563 | +€7,372 | +2.2% |
| Financial debts | 170/4 | €28,191 | €10,563 | -€17,628 | -62.5% |
| Other amounts payable | 178/9 | €300,000 | €325,000 | +€25,000 | +8.3% |
| Amounts payable within one year | 42/48 | €65,703 | €25,483 | -€40,220 | -61.2% |
| Current portion of amounts payable after more than one year | 42 | €17,040 | €17,628 | +€588 | +3.4% |
| Trade debts | 44 | €48,662 | €7,854 | -€40,808 | -83.9% |
| Suppliers | 440/4 | €48,662 | €7,854 | -€40,808 | -83.9% |
| Other amounts payable | 47/48 | €0 | - | = | |
| Accrued charges and deferred income | 492/3 | €25 | €13,115 | +€13,090 | +52046.6% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €31,916 | €36,287 | +€4,371 | +13.7% |
| Other operating charges | 640/8 | €5,217 | €3,112 | -€2,105 | -40.3% |
| Gross operating margin | 9900 | €23,288 | €29,249 | +€5,961 | +25.6% |
| Operating profit (loss) | 9901 | -€13,845 | -€10,150 | +€3,695 | +26.7% |
| Financial income | 75/76B | €3 | €4 | +€1 | +34.2% |
| Recurring financial income | 75 | €3 | €4 | +€1 | +34.2% |
| Financial charges | 65/66B | €2,095 | €1,526 | -€568 | -27.1% |
| Recurring financial charges | 65 | €2,095 | €1,526 | -€568 | -27.1% |
| Profit (loss) for the period before taxes | 9903 | -€15,937 | -€11,673 | +€4,265 | +26.8% |
| Transfer from deferred taxes | 780 | €2,843 | €2,999 | +€156 | +5.5% |
| Income taxes | 67/77 | €1 | €1 | +€0 | +35.0% |
| Profit (loss) for the period | 9904 | -€13,096 | -€8,675 | +€4,420 | +33.8% |
| Transfer from tax-exempt reserves | 789 | €6,767 | €6,727 | -€40 | -0.6% |
| Profit (loss) for the period to be appropriated | 9905 | -€6,328 | -€1,948 | +€4,380 | +69.2% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 6 October 2026 via checked.be.